While the earliest study found a reduction in CX3CL1 concentration in mild cognitive impairment or Alzheimer’s disease patients [23], more recent studies have described the existence of higher concentrations of CX3CL1 in cerebrospinal fluid and blood from Alzheimer’s disease and mild cognitive impairment patients [24,25]. Here, CX3CL1 is linked to Cognitive impairment.